Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + Tislelizumab in Advanced Solid Tumors
NCT04577963Phase 2Terminated
- Sponsor
- HUTCHMED
- Start
- Aug 2021
- Primary completion
- Jun 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in solid tumor, triple-negative breast cancer (TNBC), endometrial cancer (EC), colorectal cancer (CRC), sponsored by HUTCHMED. Started Aug 2021; status: terminated.
02
Drugs
fruquintinib
03
Conditions
solid tumortriple-negative breast cancer (TNBC)endometrial cancer (EC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04577963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04577963.